Diabetes mellitus type 2

Bydureon BCise Now Available for the Treatment of Type 2 Diabetes

By January 10, 2018

Bydrueon BCise is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Three New Type 2 Diabetes Treatments Get FDA Approval

By December 26, 2017

Steglatro, Steglujan, and Segluromet have all received FDA approval for the treatment of type 2 diabetes.

First Short-Acting Insulin Approved as a "Follow-On" Product

By December 11, 2017

The use of abbreviated pathways can reduce drug development costs so products can be offered at a lower price to patients.

Ozempic Approved to Treat Adults With Type 2 Diabetes

By December 05, 2017

The global Phase 3a clinical trial program for Ozempic comprised 8 clinical trials involving more than 8,000 adults with type 2 diabetes.

Serious Hypoglycemia Risk Compared Among Oral Antidiabetics

By November 07, 2017

Among all study drugs, the highest rate was seen with glyburide.

Bydureon BCise Gets FDA Approval for Type 2 Diabetes

By October 23, 2017

In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a sulfonylurea, a thiazolidinedione, or any combination of two of these agents, at 28 weeks.

FDA Committee Supports Semaglutide Approval for Type 2 Diabetes

By October 19, 2017

The FDA Committee's positive recommendation was based on data from the global development program, SUSTAIN, which evaluated the safety and efficacy of once-weekly semaglutide.

Do SGLT2 Inhibitors Raise the Risk of Lower Extremity Amputation?

By September 15, 2017

Study authors analyzed the occurrence of amputation in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors vs. non-SGLT2 inhibitors, and specifically, canagliflozin.

ACP: Updated Drug Therapy Recommendations for T2DM

By January 03, 2017

The update was prompted following new research evaluating medications for type 2 diabetes.

ADA Issues Guidelines for Psychosocial Care in Diabetes

By November 23, 2016

The American Diabetes Association (ADA) released its first position statement that includes detailed guidelines for psychosocial assessments and care based on factors including age, type of diabetes, and family support system.